Pharmacy World and Science

, Volume 27, Issue 2, pp 121–123 | Cite as

Gabexate mesilate and acute pancreatitis: an experience of evidence based drug information for improving rational drug use

  • Roberto BanfiEmail author
  • Giovanna Borselli
  • Silvia Cappelletti
  • Leonardo Mari
  • Massimo Aiazzi
  • Vittorio Taddei
Research Article


Introduction: Gabexate mesylate is a drug marketed only in Italy and Japan and it is considered an essential drug in the treatment of acute pancreatitis. A periodic revision and evaluation of drug utilization in our hospital demonstrated that the dosages and indications of Gabexate mesilate (GM) did not follow those settled by the National Health System and by our Hospital Formulary. We therefore promoted and conducted a program of drug information and meetings with the physicians in order to improve the correct utilisation of GM and identify potential problems.

Methods: GM prescriptions in 1999 were analysed for indications and dosages. Scheduled meetings with the medical staff were successively started in order to debate current therapies and treatments of acute pancreatitis using the criteria of evidence- based medicine (EBM). Follow-up was done in 2000, 2001 and 2002 to evaluate the efficacy of our intervention.

Results: The hospital board and 20 physicians were involved in this program of evidence-based drug information. The follow-up and the monitoring of GM prescriptions showed a reduction in the utilisation of GM in the subsequent period.

Conclusions: GM is one of the most expensive drugs in our hospital, but its benefits are not very evident. Moreover, the international guidelines and literature ascribe to GM only a marginal role in the treatment of acute pancreatitis. Evidence-based medicine strengthens clinical experience with the evidence from the literature and underlines that essential drugs are used worldwide.


Acute pancreatitis EBM Drug utilisation Evidence-based medicine Gabexate mesylate Hospital pharmacy Italy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Buchler, M, Malfertheiner, P, Uhl, W, Scholmerich, J, Stockmann, F, Adler, G.,  et al. 1993Gabexate mesilate in human acute pancreatitis.Gastroenterology104116570PubMedGoogle Scholar
  2. 2.
    Goebell, H. 1988Multicenter double-blind study of Gabexate-mesilate (Foy), given intravenously in low dose in acute pancreatitisDigestion4083Google Scholar
  3. 3.
    Valderrama, R, Perez-Mateo, M, Navarro, S, Vazquez, N, Sanjose, L, Adriàn, MJ.,  et al. 1992Multicenter double-blind trial of Gabexate mesylate (FOY) in unselected patients with acute pancreatitisDigestion516570PubMedGoogle Scholar
  4. 4.
    Pederzoli, P, Cavallini, G, Falconi, M, Bassi, C. 1993Gabexate mesilate vs aprotinine in human acute pancreatitis (GA ME. P.A.): a prospective randomized double-blind multicenter study.Int J Pancreatol1411724PubMedGoogle Scholar
  5. 5.
    Yang, CY, Chang-Chien, CS, Liaw, YF. 1987Controlled trial of protease inhibitor gabexate mesylate (Foy) in the treatment of acute pancreatitis.Pancreas2698700PubMedGoogle Scholar
  6. 6.
    Messori, A, Rampazzo, R, Scroccaro, G, Olivato, R, Bassi, C, Falconi, M.,  et al. 1995Effectiveness of Gabexate mesilate in acute pancreatitis, a metaanalysisDigest Dis Sci407348PubMedGoogle Scholar
  7. 7.
    Andriulli, A, Leandro, G, Clemente, R, Festa, V, Caruso, n, Annese, V.,  et al. 1998Meta-analysis of somatostatin, octeotride and gabexate mesilate in the terapy of acute pancreatitisAliment Pharmacol Ther1223745CrossRefPubMedGoogle Scholar
  8. 8.
    United Kingdom guidelines for the management of acute pancreatitis (1998). Gut 42 (2):S1–S13Google Scholar
  9. 9.
    Friess, H, Beger, HG, Sulkowski, U, Becker, H, Hofbauer, B, Dennler, HJ.,  et al. 1995controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitisBr J Surg8212703PubMedGoogle Scholar
  10. 10.
    Carballo, F, Domininguez, E, Fernandez-Calvet, L.,  et al. 1991Is somatostatin useful in the treatment of acute pancreatitis? A meta-analysisDigestion49123Google Scholar
  11. 11.
    Paran, H, Neufeld, D, Mayo, A, Shwartz, I, Singer, P, Kaplan, O.,  et al. 1995Preliminary report of a prospective randomized study of octreotide in the treatment of severe acute pancreatitisJ Am Coll Surg1811214PubMedGoogle Scholar
  12. 12.
    Fiedler, F, Jauernig, G, Keim, V, Richter, A, Bender, HJ. 1996Octreotide treatment in patients with necrotising pancreatitis and pulmonary failureIntens Care Med2290915CrossRefGoogle Scholar
  13. 13.
    McKay, C, Baxter, J, Imrie, C. 1997A randomized controlled trial of octeotride in the management of patients with acute pancreatitis. Int J Pancreatol21139Google Scholar
  14. 14.
    Imrie, CW, Benjamin, IS, Ferguson, JC, McKay, AJ, Mackenzie, I, ONeill, J,  et al. 1978A single-centre, double-blind trial of trasylol therapy in primary acute pancreatitisBr J Surg6533740PubMedGoogle Scholar
  15. 15.
    Berling, R, Genell, S, Ohlsson, K. 1994High-dose intraperitoneal aprotinin treatment of acute severe pancreatitis : a double-blind randomized multi-centre trialJ Gastroenterol2947985PubMedGoogle Scholar
  16. 16.
    Wyncoll, DL. 1999The management of severe acute necrotising pancreatitis: an evidence-based review of the literatureIntens Care Med2514656CrossRefGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Roberto Banfi
    • 1
    Email author
  • Giovanna Borselli
    • 1
  • Silvia Cappelletti
    • 2
  • Leonardo Mari
    • 1
  • Massimo Aiazzi
    • 1
  • Vittorio Taddei
    • 3
  1. 1.Pharmacy DepartmentHospital MugelloBorgo San LorenzoItaly
  2. 2.Pharmacy DepartmentHospital Nuovo San Giovanni di DioFlorenceItaly
  3. 3.Pharmacy Department DiretorFlorenceItaly

Personalised recommendations